The report provides a comprehensive study of hemophilia market globally. For more mail: vikas@konceptanalytics.com

1. Global Hemophilia Market
-----------------------------------------------------
2015
View Report Details

2. Executive Summary
Hemophilia is an inherited or acquired bleeding disorder that prevents blood from clotting. People with hemophilia lack, either partially
or completely, an essential clotting factor needed to form stable blood clots. People with hemophilia do not bleed any faster than
normal, but they can bleed for a longer time. Hemophilia is quite rare and about 1 in 10,000 people are born with it, around 0.42 million
people live with hemophilia. Hemophilia patients need to replace the missing factor through infusions. The main treatment is called
replacement therapy, in which concentrates of clotting factor VIII (for hemophilia A) or clotting factor IX (for hemophilia B) are injected
into a vein. More people suffer with hemophilia A in comparison to hemophilia B and Inhibitors. The US accounts for the major
population suffering with hemophilia globally.
The key trends observed in the market include introduction of new products increased competition in rFVIII market and adoption of
prophylactic treatment. On the development front, there has been an increase in the launch of new products like next-Generation long-
acting Factor VIII and ready-to-use product by Novo Nordisk. But there are certain challenges too which include high risk and cost
associated with new drugs, rising cost of hemophilia treatment and low switching rate among patients. The future drivers of the industry
are increased rate of diagnosis and treatment, rising male population and global healthcare expense among others.
The report provides a comprehensive study of hemophilia market globally and also provides detailed information for key regional
markets. The competition in the global hemophilia market is intense among large players like Baxter International Inc., Novo Nordisk
and Pfizer. All these companies have been profiled in the present report highlighting their key financials and business strategies for
growth.
By combining SPSS Inc.’s data integration and analysis capabilities with our relevant findings, we have predicted the future growth of
the industry. We employed various significant variables that have an impact on this industry and created regression models with SPSS
Base to determine the future direction of the industry. Before deploying the regression model, the relationship between several
independent or predictor variables and the dependent variable was analyzed using standard SPSS output, including charts, tables and
tests.
View Report Details

3. Hemophilia is quite rare and about 1 in 10,000 people are born with it, around 0.42 million people live with
hemophilia.
• Hemophilia market is divided into four segments. According to
2014 estimates, hemophilia A makes up the majority of the
hemophilia market with …% of market share whereas hemophilia B
makes only …% of the market share. Hemophilia with inhibitors
has …% share, at second position, while Von Willebrand Disease
(VWD) has a small …% share.
•The broader hemophilia market is estimated to have grown from
US$... billion in 2011 to US$... billion in 2014, representing an
average …% growth rate over this period mainly due to increased
use of prophylaxis in developed countries, as well as
pharmaceutical companies’ expansion of markets into underserved
countries.
•Globally, hemophilia A type accounts for …% of hemophilic
patients with … patients followed by hemophilia B with … patients
as of 2014. Inhibitor segment accounts for …% share with … to …
patients.
Hemophilia Patients by Type (2014)Global Hemophilia Market Value (2010-2014E)
Hemophilia Market by Segments (2014E)
2010 2011 2012E 2013E 2014E
US$Billion
Hemophilia A Hemophilia B Hemophilia A+B with inhibitors
Hemophilia A Hemophilia B
Hemophilia A+B with inhibitors Von Willebrand Disease

4. Worldwide, the estimate of prophylactic use amongst the patient population was only 17%.
• The global hemophilia A (Factor VIII) market is worth nearly
US$... billion according to 2014 estimates, of which recombinant
therapies (rFVIII) represent over US$... billion of the market while
plasma-derived factors represent the remaining share. The
hemophilia A market is expected to reach US$... billion by 2016 at
a CAGR of …% over the period 2011 to 2016.
•Global FVIII estimates for unit demand growth over the period
2014-2016 of …% per annum, is slightly elevated compared to …%
growth observed in the previous three years i.e. 2010 to 2012. As
of 2014, the demand is … million units. A key factor that could
augment the demand growth outlook in hemophilia A, particularly in
emerging markets is the increased use of prophylactic treatment.
• In 2012, … thousand patients suffering from hemophilia A had
been treated and the figure is estimated to have risen to …
thousand patients in 2014 depicting an increase of …%. Moreover,
the number of treated patients is likely to rise further in future as
well.
Hemophilia A Patients Treated Per Year Globally (2010-2017E)Global Demand for Factor VIII (2010-2016E)
Global Hemophilia A Market Value (2011-2016E)
0
2,000
4,000
6,000
8,000
10,000
12,000
2010 2011 2012 2013E 2014E 2015E 2016E
MillionUnits
0
20
40
60
80
100
120
140
160
2010 2011 2012 2013E 2014E 2015E 2016E 2017E
ThousandPatients
0.0
1.0
2.0
3.0
4.0
5.0
6.0
7.0
8.0
2011 2012E 2013E 2014E 2015E 2016E
US$Billion

5. The global hemophilia market is controlled by five major players: Baxter, Novo Nordisk, Pfizer, Bayer and
CSL Behring.
•The global hemophilia B (Factor IX) market was nearly US$... billion
market in 2014, approximately one-fourth the size of the hemophilia A
market. The hemophilia B market is expected to reach US$... billion by
2016 at a CAGR of …% over the period 2011 to 2016.
•The number of new market entrants in the rFVIII space will surpass the
number of existing players and could displant the stronghold that Baxter
currently has on …% of the rFVIII market as of 2013. Bayer’s Kogenate
and Pfizer makes up …% and …% of the market share as of 2013
respectively.
•The global hemophilia A market is dominated by Baxter (Advate)
making up …% of the market share followed by Bayer (Kogenate), with
…% of share as of 2014. Pfizer (Refacto) and CSL Behring (Helixate)
make up …% and …% of the market share respectively in 2014, and
the rest …% of the market is plasma derived.
Hemophilia A Market Share by Company (2014)Recombinant FVIII Market Share by Company (2013)
Global Hemophilia B Market Value (2011-2016E)
2011 2012E 2013E 2014E 2015E 2016E
US$Billion
Baxter (Advate) Bayer (Kogenate)
Pfizer (Refacto) CSL Behring (Helixate)
Plasma derived
Baxter Bayer CSL Behring Pfizer

6. Novo Nordisk has a very strong and long-standing presence in the market with NovoSeven which targets
hemophilia Factor VIII and Factor IX patients with inhibitors.
Hemophilia is more likely to occur in males than females. This is because females have two X chromosomes while males have only one, so
the defective gene is guaranteed to manifest in any male who carries it. Because females have two X chromosomes and hemophilia is rare, the
chance of a female having two defective copies of the gene is very remote, so females are almost exclusively asymptomatic carriers of the
disorder. The incidence rate is 1 in every 50,000 male births for hemophilia A and 1 in 20,000 male births in case of hemophilia B. The global
male population increased from … billion in 2010 to … billion in 2014 at a CAGR of …% and is estimated to increase to around … billion by
2025.
Since hemophilia is a rare disorder, this obviously limits the size of the market and the number of customers. Currently about 20,000 people
have hemophilia in the US, about …% of them have hemophilia A, and 3,000 to 4,000 have hemophilia B. About 400 US babies with hemophilia
are born each year. According to 2014 estimates, US hemophilia A market is worth US$... billion and hemophilia B market is worth US$...
billion. The sales per patient in case of hemophilia A and B is US$... and US$... respectively.
The global hemophilia market increased from US$... billion in 2011 to US$... billion in 2014 showing an increase of …%. This increase was
mainly due to increasing male population, increasing hemophilia A patients treated per year globally and rising health expenditure per capita.
The market is forecasted to reach US$... billion in 2015 showing a rise of …% versus prior year. This continuous growth is also due to rising
awareness among the people about the treatment and innovation in tools and techniques related with the hemophilia, in particular with greater
adoption of prophylactic treatment. The global hemophilia treatment market is expected to grow at a CAGR of …% for the period spanning
2014-2018.
Note: Market attractiveness is inverse of penetration. Low penetration means high attractiveness and vice-versa
Global Male Population (2010-2014)
2014
2015F
2016F
2017F
2018F
US$Billion
Global Hemophilia Market Forecast (2014-2018F)2010
2011
2012
2013
2014
Billion

7. Koncept Analytics
CS-36, Second Floor, Ansal Plaza
Vaishali, Ghaziabad,
U.P. – 201010
T. +91-120-4130959
C: +91-9811715635
vikas@konceptanalytics.com
Contact Us:
www.konceptanalytics.com
Vikas Gupta
BD Manager
These are abridged and sanitized sample pages from the comprehensive report on the “ Global Hemophilia Market ”. To know
more about this report or for any customized research requirement, please contact the following:
View Report Details